Focuses on developing novel therapies for central nervous system disorders by targeting mitochondrial function and neuroinflammation.
Gyre Therapeutics, Inc., a leading pharmaceutical firm, specializes in advancing small-molecule therapies targeting organ fibrosis with a focus on anti-inflammatory and anti-fibrotic drugs.
The company's flagship product, ETUARY (Pirfenidone), has received approval as an anti-fibrotic treatment for idiopathic pulmonary fibrosis. Currently, ETUARY is undergoing Phase 3 trials for conditions such as dermatomyositis, systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease.
Gyre Therapeutics is also actively developing F351 (Hydronidone), a derivative of ETUARY, in Phase 3 studies for chronic hepatitis B liver fibrosis and Phase 1 trials for liver fibrosis associated with nonalcoholic steatohepatitis. The company's robust pipeline includes F573 in Phase 2 trials for acute/acute-on-chronic liver failure, F528 in preclinical stages for chronic obstructive pulmonary disease, and F230 in preclinical development for pulmonary arterial hypertension.
Founded in 2002 and headquartered in San Diego, California, Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc., dedicated to advancing therapies that address significant unmet needs in organ fibrosis treatment.